Henk Jan Guchelaar
Overview
Explore the profile of Henk Jan Guchelaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beunk L, Nijenhuis M, Soree B, de Boer-Veger N, Buunk A, Guchelaar H, et al.
Eur J Hum Genet
. 2023 Mar;
32(3):278-285.
PMID: 37002327
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy. A guideline describing the gene-drug interaction between the genes...
2.
Guglieri-Lopez B, Perez-Pitarch A, Moes D, Porta-Oltra B, Climente-Marti M, Guchelaar H, et al.
Cancer Chemother Pharmacol
. 2017 Jan;
79(1):189-200.
PMID: 28039509
Purpose: Lenalidomide disease-specific toxicity profiles and potentially life-threatening adverse events support the consideration of diversity in starting doses. The aim of this study was to conduct a population pharmacokinetic analysis...
3.
Moes D, Press R, Ackaert O, Ploeger B, Bemelman F, Diack C, et al.
Br J Clin Pharmacol
. 2016 Jun;
82(1):227-37.
PMID: 27334415
Aims: This study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR)....
4.
5.
van Staveren M, Theeuwes-Oonk B, Guchelaar H, van Kuilenburg A, Maring J
Cancer Chemother Pharmacol
. 2011 May;
68(6):1611-7.
PMID: 21590448
Purpose: Dihydropyrimidine dehydrogenase (DPD) deficiency can lead to severe toxicity in patients treated with standard doses of 5-fluorouracil (5-FU). Oral uracil administration and subsequent measurement of uracil and dihydrouracil (DHU)...
6.
Pander J, Guchelaar H, Gelderblom H
Curr Opin Mol Ther
. 2010 Dec;
12(6):654-61.
PMID: 21154157
Cancer treatment has undergone revolutionary changes during the past decade, as a result of the introduction of tyrosine kinase inhibitors (TKIs) that selectively inhibit growth factor pathways critical for tumor...
7.
Koomen E, de Vries E, van Kempen L, van Akkooi A, Guchelaar H, Louwman M, et al.
Cancer Epidemiol Biomarkers Prev
. 2010 May;
19(6):1453-9.
PMID: 20501769
Background: Reliable population-based incidence and survival data on extracutaneous melanoma (ECM) are sparse. Methods: Incidence data (1989-2006) from the Netherlands Cancer Registry were combined with vital status on January 1,...
8.
Koomen E, Joosse A, Herings R, Casparie M, Guchelaar H, Nijsten T
Melanoma Res
. 2009 Jul;
19(5):327-32.
PMID: 19593232
Recently, we showed there was a cumulative dose-dependent association between the use of estrogens and the incidence of cutaneous melanoma (CM). This association was shown for both oral contraceptives (OC)...
9.
Schellens J, Grouls R, Guchelaar H, Touw D, Rongen G, de Boer A, et al.
Br J Clin Pharmacol
. 2008 Mar;
66(1):146-7.
PMID: 18341674
No abstract available.